So there's still quite a bit to be done. While the House is obviously going to support this, there are still some caveats. We can explore them in the committee of the whole House, but I do implore the Health Committee to keep in touch with Pfizer and with Treasury or the Ministry of Health on whether or not the extraordinary further outlay is going to be exceeded by the benefits in reduced harm.